Piperacillin
Based on 16 publication(s) in Google Scholar
Piperacillin is a semisynthetic broad-spectrum β-lactam antibiotic which exhibits potent bactericidal activity against Gram-negative bacteria as well as select Gram-positive strains through penicillin-binding proteins. Piperacillin is most commonly used in combination with the β-lactamase inhibitor Tazobactam.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.14%
- No. CAS: 61477-96-1
- Fòrmula: C23H27N5O7S
- Peso molecular:517.55
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Piperacillin
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- Int J Antimicrob Agents. 2025 Oct;66(4):107551. [Abstract]
- PLoS Pathog. 2024 Dec 31;20(12):e1012783. [Abstract]
- Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- Microbiol Spectr. 2023 Jun 15;11(3):e0069223. [Abstract]
- Microbiol Spectr. 2023 Feb 14;11(1):e0303822. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- Biomed Res Int. 2018 Jul 2:2018:3579832. [Abstract]
- medRxiv. 2025 Mar 13:2025.03.11.25323422. [Abstract]
- bioRxiv. 2024 May 10.
Ver todos los productos específicos de isoformas Antibiotic
MoreVer todos los productos específicos de isoformas Beta-lactamase
More
Actividad biológica
|
β-lactam |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
1226 μM
Compound: piperacillin
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
Piperacillin (12.5 μg/mL, 24h) inhibits 92% of isolates of Pseudomonas aeruginosa, 82% of Serratia marcescens, 73% of Escherichia coli, 61% of Klebsiella spp, and 42% of Enterobacter spp, most Proteus spp. were extremely susceptible. Piperacillin fails to inhibit the growth of gram-negative bacilli when large inocula were used (minimum inhibitory concentration >25 μg/mL) [2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c low inoculum model of K. pneumoniae, KEN-11 strain [3]
-
Dosage:100 mg/kg
-
Administration:Intravenous injection (i.v.), 4 times a day, 5 d, in combination with Tazobactam (12.5 mg/kg, i.v., 4 times a day, 5 d)
-
Result:Enabled all mice survived whereas all control mice died by 5 d, decreased the number of bacteria in lungs compared with control group[.
Observed no bacteria in the blood of most mice (except for two mice at the early phase) while bacteria were observed in the blood of control group.
Observed few inflammatory cells in the alveoli whereas an influx of numerous inflammatory cells were observed in the control group.
Chemical Information
-
No. CAS 61477-96-1
-
Appearance Solid
-
Peso molecular 517.55
-
Fòrmula C23H27N5O7S
-
Color White to off-white
-
SMILES
O=C([C@@H](C(C)(C)S[C@]1([H])[C@@H]2NC([C@H](NC(N3C(C(N(CC)CC3)=O)=O)=O)C4=CC=CC=C4)=O)N1C2=O)O
-
Synonyms
Pipracil
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
Virulence
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]2026 Dec 31;17(1):2646808. PMID: 41838520 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
Int J Antimicrob Agents
Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]2025 Oct;66(4):107551. PMID: 40499596 -
PLoS Pathog
Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. [Abstract]2024 Dec 31;20(12):e1012783. PMID: 39739989 -
Antimicrob Agents Chemother
Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology. [Abstract]2023 Jun 15;67(6):e0160322. PMID: 37199612 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
Microbiol Spectr
Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae. [Abstract]2023 Jun 15;11(3):e0069223. PMID: 37093051 -
Microbiol Spectr
PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. [Abstract]2023 Feb 14;11(1):e0303822. PMID: 36475840 -
-
Biomed Res Int
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]2018 Jul 2:2018:3579832. PMID: 30065936 -
medRxiv
The association between undetected heteroresistance and antibiotic treatment failure in complicated urinary tract infection. [Abstract]2025 Mar 13:2025.03.11.25323422. PMID: 40162257 -
Solvente y solubilidad
DMSO : 100 mg/mL (193.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Fu KP, et al. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother. 1978，13(3):358-67. [Content Brief]
[2]. Bodey GP, et al. Piperacillin: In Vitro Evaluation. Antimicrob Agents Chemother. 1978，14(1):78-87. [Content Brief]
[3]. Harada Y, et al. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect. 2014，20(11):O831-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9322 mL | 9.6609 mL | 19.3218 mL | 48.3045 mL |
| 5 mM | 0.3864 mL | 1.9322 mL | 3.8644 mL | 9.6609 mL | |
| 10 mM | 0.1932 mL | 0.9661 mL | 1.9322 mL | 4.8305 mL | |
| 15 mM | 0.1288 mL | 0.6441 mL | 1.2881 mL | 3.2203 mL | |
| 20 mM | 0.0966 mL | 0.4830 mL | 0.9661 mL | 2.4152 mL | |
| 25 mM | 0.0773 mL | 0.3864 mL | 0.7729 mL | 1.9322 mL | |
| 30 mM | 0.0644 mL | 0.3220 mL | 0.6441 mL | 1.6102 mL | |
| 40 mM | 0.0483 mL | 0.2415 mL | 0.4830 mL | 1.2076 mL | |
| 50 mM | 0.0386 mL | 0.1932 mL | 0.3864 mL | 0.9661 mL | |
| 60 mM | 0.0322 mL | 0.1610 mL | 0.3220 mL | 0.8051 mL | |
| 80 mM | 0.0242 mL | 0.1208 mL | 0.2415 mL | 0.6038 mL | |
| 100 mM | 0.0193 mL | 0.0966 mL | 0.1932 mL | 0.4830 mL |
Piperacillin Related Classifications
HY-B1923 Related Classifications
Powered by Bioz